Skip to content

Trump’s Drug Pricing Reforms Fall Short

In a pair of “midnight rules,” the Trump administration finalized a policy that increases seniors’ premiums and federal spending, and moved ahead with another policy that would have to be redesigned to effectively lower drug costs without compromising access. Both rules fail to directly address manufacturers’ prices, a key culprit of skyrocketing prescription drug costs. Read more...

Prescription Drug Importation Fuels More Questions than Answers

President Trump announced that the country will move forward with drug importation, and the FDA has finalized a rule, but it remains unclear how and whether the policy will lower prices for patients, employers, or taxpayers. Read more...

President Trump’s 'Most Favored Nation' Executive Order Won’t Lower Drug Prices Immediately

President Trump signed and published an executive order intended to lower drug prices in the Medicare program by tying them to the lower prices paid in other countries. While the path forward is uncertain, one thing is clear — the proposal shares a provision that was a key component of House Democrats’ signature drug pricing bill, H.R. 3. Read more...

Executive Orders Unlikely to Lower Drug Prices

President Trump announced four executive orders to bring attention to prescription drug prices. But details of Trump's actions reveal little impact on patients, employers, or taxpayers. Read more...

'Buy American' Rule Aimed at Lessening Dependence on Foreign Drug Manufacturing Could Lead to Higher Prices

President Trump’s latest executive order on prescription drugs attempts to stabilize some pharmaceutical supply chain issues, but the potential impacts of the mandate are highly uncertain. Read more...


Grants

Arnold Ventures funds projects to understand problems and identify policy solutions.

Map of the U.S. made of Arnold Ventures icons